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OBJECTIVES: Most educational interventions in pharmacovigilance are designed to encourage physicians to
report adverse drug reactions. However, multidisciplinary teams may play an important role in reporting drug-
related problems. This study assessed the impact of a multifaceted educational intervention in pharmacov-
igilance on the knowledge, skills and attitudes of hospital professionals.
METHOD: This prospective, open-label, non-randomized study was performed in a medium-complexity hospital
in Sa˜o Paulo, Brazil. The intervention involved four activities: 1) an interactive lecture, 2) a practical class, 3) a
pre-post questionnaire administered to professionals on a multidisciplinary team, and 4) educational material.
The intervention’s impact on the professionals’ knowledge and skills was assessed using the World Health
Organization’s definitions. The intervention’s effect on the professionals’ attitudes was analysed by the
prevalence of adverse drug event reports (adverse drug reactions, medication errors, therapeutic failure and
drug quality deviations) and the relevance (seriousness and expectancy) of the events.
RESULTS: One hundred seventy-three professionals were enrolled. A 70-fold increase in the number of adverse
drug event reports was observed during the 12 months post-intervention. The intervention improved the
professionals’ form-completion skills (po0.0001) and their knowledge of pharmacovigilance (po0.0001). The
intervention also contributed to detecting serious drug-induced events. The nursing staff reported medication
errors, and pharmacists and physiotherapists recognized serious adverse drug reactions. Physicians commu-
nicated suspicions of therapeutic failure.
CONCLUSIONS: A multidisciplinary approach to drug-safety assessments contributes to identifying new,
relevant drug-related problems and improving the rate of adverse drug event reporting. This strategy may
therefore be applied to improve risk communication in hospitals.
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’ INTRODUCTION
Although the limitations of traditional systems designed to
detect adverse drug events (ADEs) are well known (1),
spontaneous reporting remains the cornerstone of post-
marketing drug safety surveillance (1,2).
The use of spontaneous reporting persists because new
approaches that have been developed to improve risk com-
munication (e.g., electronic health record databases) may not
have enough exposure to new drugs (3). Consequently,
spontaneous reporting should continue to be used in phase
IV studies to provide information regarding the safety and
effectiveness of drug use (3) and to detect unexpected and
serious events (4).
There are a limited number of professionals with knowl-
edge of pharmacovigilance around the world (5). However,
the number of health employees with competencies related
to drug surveillance in low- and middle-income countries is
very low, as there are often limited financial resources avai-
lable in these countries to support attendance at professional
development courses in pharmacovigilance (5). Consequently,
there are a limited number of professionals in developing
countries capable of performing drug safety assessments (5-7)
and improving risk management.DOI: 10.6061/clinics/2017(01)09
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Although the contributions of Latin American countries to
the field of pharmacovigilance has increased in recent years
(8), a minority of Latin American nations invest in profes-
sional training (9-10). Therefore, biases in epidemiological
communication (11) and impairments in signal detection
result from the lack of robust information available during
the post-marketing life cycle of drugs.
Several strategies have been implemented to promote
adherence to appropriate pharmacovigilance practices among
health professionals in pharmacovigilance services, and these
have primarily involved designing educational interventions
(12-14), including subjects related to drug safety assessments
in both undergraduate and postgraduate programs (15), and
increasing the amount of time dedicated to teaching pharma-
covigilance in universities (16). The most important objective
of these educational interventions is to develop functional and
behavioural competencies (17) to promote changes in attitude
among physicians and pharmacists towards adverse drug
reaction (ADR) reporting. These educational interventions do
not include other types of ADEs, such as medication errors,
therapeutic failure and drug quality deviations. Consequently,
drug-induced harm is underreported.
Given the constraints of healthcare assistance in low- and
middle-income countries (brief contact between physicians
and patients, lack of time to report drug-related problems
and lack of information in patients’ records about drug
safety), the responsibility for ADEs must be shared among
trained healthcare professionals (pharmacists, nurses) (5) to
decrease underreporting (10). However, studies of multi-
disciplinary teams are scarce in the literature.
Based on these considerations, the current study aimed
to 1) assess the impact of a multifaceted educational inter-
vention (MEI) on the prevalence of ADE reporting (attitude)
by multidisciplinary teams, 2) evaluate the effectiveness of
the MEI on professionals’ knowledge of and skills in
pharmacovigilance and their fulfilment of ADE reporting
requirements, and 3) assess the degree of relevance of the
ADE reports submitted after the MEI according to the events’
seriousness and likelihood of occurrence.
’ MATERIALS AND METHODS
Study population and setting
The study was conducted in a medium-complexity,
general and public hospital with 94 beds. The hospital is
located in the Araraquara-São Carlos region (São Paulo
State, Brazil), which comprises 24 municipalities and
includes over one million inhabitants. The hospital is
known for providing healthcare for infectious diseases and
neurologic rehabilitation (approximately 13,000 appointments
per month).
The inclusion criteria comprised all hospital staff (physi-
cians, pharmacists, nurses, auxiliary nursing and pharmacy
staff, and administrative officers, as well as social assistants,
physiotherapists, audiologists, nutritionists, psychologists,
and occupational therapists) with an employment link to the
hospital who agreed to participate by signing an informed
consent form. The exclusion criteria included professionals
who were on sick leave or vacation, those who were not eli-
gible to participate in the intervention and those who
declined to respond to the questionnaire despite having
shown interest in the intervention by participating in the
lecture and practical class.
Design of the study
A longitudinal, prospective, open-label and non-randomized
study using a single group before-and-after intervention design
(18) was conducted from 1 February 2012 through 31 May
2012. A before-and-after design measures the performance of
one or more subjects after the introduction of an intervention to
assess the intervention’s effect (19).
Although randomized controlled trials represent the most
suitable research design for evaluating the effectiveness of an
intervention, (20) we were unable to design a randomized
controlled trial due to the unavailability of an appropriate
control group. Therefore, we opted to use the before-and-
after design due to its simplicity and its robustness relative to
observational research (19). Furthermore, findings in the
literature have demonstrated the positive impact of educa-
tional interventions in pharmacovigilance on changing the
behaviour of health professionals (12,13). Additionally,
because the introduction of an intervention may improve
risk communication, we decided that ethical principles could
not be satisfied if a control group was unable to benefit from
the acquisition of knowledge regarding drug safety assess-
ments through the intervention.
Multifaceted educational intervention
The applied MEI model was first proposed by Pagotto et al.
(2013) (12). To assess the reproducibility of the method, a pilot
study was conducted in six hospital institutions in Mercosur
member countries (10). Briefly, the MEI involved four different
activities: a lecture on pharmacovigilance concepts and the
landscape of pharmacovigilance; a practical class on how to
correctly complete ADE reports; the distribution of educa-
tional materials and the administration of a questionnaire to
the participating professionals before and after the MEI. These
activities were conducted during four separate sessions, each
of which lasted one hour.
In the first session, the pre-test assessment was adminis-
tered via questionnaire. The instrument’s development and
the determination of its concepts and constructs of interest
were based on the literature (10). The questionnaire included
three sections: the first section related to knowledge asses-
sment (five essay questions about the importance of pharma-
covigilance), the second section focused on attitudes (five
essay questions related to ADE reporting) and the third
section consisted of an evaluation of the professional’s skills
regarding information that is considered essential, necessary
and unnecessary on an ADE report. This portion of the study
was designed to obtain baseline data about the hospital
staff members’ knowledge, skills and attitudes related to
pharmacovigilance.
The second and third sessions involved lectures, a practi-
cal class, and the distribution of educational material to
multidisciplinary teams of hospital staff. The post-test
assessment was conducted during the final session. The
participants were asked to fill out the same questionnaire
they completed in the first session to enable an evaluation
the effectiveness of the intervention on their knowledge,
skills and attitudes (10).
Follow up and outcome measures
The knowledge assessment was performed by analysing
the responses to the questionnaire; each item on the ques-
tionnaire was assigned a score ranging from 0–10. The World
Health Organization’s definitions for pharmacovigilance (21)
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were considered gold-standard answers (Table 1). Scores
below 5 were considered unsatisfactory, scores between 5
and 7.5 were considered average and scores above 7.6 were
considered satisfactory in terms of knowledge acquisition.
The skills evaluation was based on the professionals’
perception of the degree of relevance of the information
reported on an ADE form. Accordingly, the professionals were
asked to highlight the ADE form fields according to whether
the data required for those fields are considered unnecessary,
necessary or essential. The minimal and desirable criteria to
be supplied in an ADE form were defined according to the
recommendations of the Pan-American Health Organiza-
tion (22) (Table 1). The Wilcoxon-Mann-Whitney statistical
test was used to assess the impact of the MEI on the parti-
cipants’ knowledge and skills. Statistical significance was set
at po0.05.
Table 1 - Criteria considered to be gold standard in terms of knowledge [32] and skill [2] assessment in pharmacovigilance.
KNOWLEDGE GOLD-STANDARD ANSWERS SKILLS GOLD-STANDARD ANSWERS
1) What is pharmacovigilance? The monitoring of medicine use for the
detection, assessment and prevention
of adverse drug reactions and any issues
related to medicine.
1) ADR reporting
1.1) Minimal
criteria
About the patient: name, medical record
number, bed, gender, clinical history
(illness, comorbidities, drug allergies).
2) Does the practice of
pharmacovigilance promote
benefits? When positive, what
are the benefits
and who are the beneficiaries?
The practice of pharmacovigilance promotes
benefits for drug users, professionals and
healthcare institutions. The benefits include
contributing to patient safety, improving the
quality of care in health facilities, and ensuring
that drugs on the pharmaceutical market are
safe, effective and high quality.
About ADR: clinical manifestations (treatment
initiation and finalization), evolution
(outcomes), laboratory tests, treatment
(hospitalization, discontinuation of drugs,
prescription of drugs).
About the suspected drug: drug, dose, route
of administration, indication, date of
treatment initiation and finalization, expiry
date, lot number and manufacturer.
3) Who may notify? Drug users, health professionals and the
pharmaceutical industry.
About polypharmacy: drugs, dose, route of
administration, date of treatment initiation
and finalization, expiry date, lot number and
manufacturer.
4) What can you notify? Any drug-related problems, especially adverse
drug reactions, medication errors, therapeutic
ineffectiveness and drug-quality deviations.
About the reporter: name, profession,
telephone number or e-mail and date that the
report was made.
5) What do you mean by: 1.2) Desirable
criteria
About the patient: risk factors for ADR
occurrence (kidney and/or hepatic failure,
previous exposure to the drug, alcohol
consumption or a smoking habit).
a) Adverse drug event? Any damage or harm caused to patients
arising from drug use.
b) Adverse drug reaction? A response to a drug that is noxious and
unintended and that occurs at doses normally
used in humans for prophylaxis, diagnosis,
therapy of disease, or for modifications to
physiological function.
About the ADR: clinical evolution (outcomes),
documentation of diagnoses (including
procedures applied, data from laboratory
tests and pharmacological treatment).
c) Medication errors? Any preventable event that may cause
or lead to inappropriate medication
use or patient harm while the medication
is in the control of the healthcare
professional, patient, or consumer.
2) Medication
error reporting
d) Quality drug deviations? A departure from the quality parameters
established for a product or process. In
pharmacovigilance, these deviations can
include organoleptic changes that are either
physico-chemical and/or general (leaks,
inadequate labelling, foreign particles, etc.).
2.1) Desirable
criteria
About the product: the product involved in
the error (dose, route of administration,
expiry date, lot number, type of packaging,
label, etc.).
e) Suspicious of therapeutic
ineffectiveness?
The total or partial absence of the expected
effect of the drug on the condition of use
prescribed or indicated in the leaflet.
About the place: where the error occurred
(appropriateness to carrying out the activities,
promotes distractions, considerable noise,
etc.), medical equipment and products used
(meet the attributes of quality and safety),
service flow, etc.
6) What is the correlation
between pharmacovigilance
and drug safety?
The practice of pharmacovigilance, monitoring
drug use, contributes to the regulation of the
pharmaceutical market because it focuses on
the safety, quality and effectiveness of these
products.
About the person involved: characterize
regarding time of graduation, time of
employment, duty period, aetiologic causes
and contributing factors.
7) How would you explain why
a drug does not produce the
desired effect?
The medicine may not produce the desired effect
for three primary reasons: the inherent
characteristics of the patient, medication errors
and quality deviation.
8) In which stages of drug use
can medication errors occur?
In all stages: prescribing, dispensing and
administration.
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To analyse the impact of the MEI on the attitudes and
behaviour of the participating professionals, the absolute
number of ADE reports (ADR, therapeutic failure, medication
errors and quality deviations) 12 months prior to the interven-
tion (t0) were investigated. A year of follow up regarding the
absolute number of ADEs reported post-intervention was
also performed (t2) to assess changes relative to t0.
The Mann-Whitney statistical test was used to identify
significant differences between the proportions of the
number of ADE reports/the number of hospitalized patients
before the educational intervention (t0) and after the
educational intervention (t2). An evaluation of the effective-
ness of the MEI on ADE reporting was performed using
segmented generalized linear regression models. Adjustment
segmentation was conducted by including a variable that
represented the period over which the MEI occurred (t1).
The relevance of the ADR and medication error reports
made during the study period was also evaluated (serious-
ness and expectancy of occurrence). The seriousness of
medication errors was assessed according to the standards of
the National Coordinating Council for Medication Error
Reporting and Prevention (23). Serious ADRs were defined
as those causing hospitalization, those that were fatal or life-
threatening, or those that resulted in significant changes in
patient treatment (thereby prolonging hospitalization) (24).
Informational drug sheets approved by the National Agency
of Sanitary Surveillance (ANVISA) and monographs, such as
those in the DRUGDEX (MICROMEDEXsdatabase), Upto-
dates database and LexiComp Manole (2009), were con-
sulted to verify the expectancy of an ADR.
Approval by the ethics committee and clinical trial
registration
The study (protocol E-015/10) was approved by the Ethics
Committee in Research of the Instituto Lauro de Souza Lima.
The protocol for the research was registered (identification
number: NCT02134587).
’ RESULTS
During the study, the staff of the hospital included 421
professionals, of whom 334 (79.3%) satisfied the inclusion
criteria. Of these 334 individuals, 203 (60.8%) returned the
questionnaire; however, only 173 staff members (51.7%)
completed the intervention. One hundred thirty-one subjects
(48.2%) attended at least one of the intervention sessions.
The MEI was effective at increasing knowledge in
pharmacovigilance among the 173 professionals who partici-
pated in all the sessions (po0.0001). Prior to the intervention,
the professionals’ knowledge was classified as unsatisfactory,
whereas post-intervention it was classified as average. The
MEI also improved the professionals’ skills in filling out ADE
forms (po0.0001) (Table 2), mainly among the physicians,
nurses and pharmacy auxiliaries (Table 2). The skills of the
other professionals remained at the average level (Table 2).
Prior to the MEI (t0), only three ADE reports had been
submitted, all of which related to therapeutic failure. After
12 months of follow up, 215 ADEs were reported. Of these
ADEs, 166 corresponded to medication errors, 26 corre-
sponded to ADRs, 18 corresponded to quality deviations and
5 corresponded to therapeutic failures. Therefore, the MEI
increased the absolute number of ADE reports by 70-fold.
The prevalence of major ADEs reported prior to the MEI
(t0) was 0.2%, and the prevalence increased to 3.9% after the
MEI (t2) (Figure 1). According to the Mann-Whitney test,
there was a significant difference between the proportion of
ADE reports/inpatients following the educational interven-
tion (p=0.003). The data suggest that the MEI promoted
changes in the participants’ behaviours and attitudes related
to ADE reporting. According to the segmented generalized
Table 2 - Adherence of hospital staff and the impact of educational interventions on knowledge related to pharmacovigilance and
skill filling out forms related to adverse drug events according to professional classification (N=173). Ame´rico Brasiliense-SP (Brazil).
Professional Adherence Impact
Answered the
questionnaire
(N)
Number
employed
(N)
Return
rate (N)
Knowledge Skills
Before Mi
(min-max)
After Mi
(min-max)
p-value Before Mi
(min-max)
After Mi
(min-max)
p-value
Physicians 11 86 12.8 4.3 (2.9-6.6) 5.0 (0.4-9.3) 0.006* 4.0 (0.0-7.9) 5.2 (0.0-9.2) 0.007*
Multidisciplinary team
Social assistant 4 5 80.0 3.9 (1.3-5.4) 6.3 (4.8-9.3) o0.0001* 5.2 (3.8-6.2) 6.1 (4.7-7.9) o0.001*
Pharmacist 1 2 50.0 4.8 (NA) 5.9 (NA) 0.0 (NA) 0.0 (NA)
Physiotherapist 10 12 83.3 2.1 (1.0-6.0) 5.8 (4.3-9.2) 5.4 (3.1-7.7) 6.8 (4.5-7.7)
Audiologist 2 4 50.0 1.2 (0.1-2.4) 6.2 (4.8-7.6) 6.7 (6.2 -7.2) 5.0 (2.9-7.1)
Nutritionist 5 5 100.0 3.0 (2.0-3.7) 5.8 (4.6-7.4) 5.7 (5.3-6.7) 7.5 (4.7-8.3)
Psychologist 3 4 75.0 2.7 (2.1-3.4) 6.2 (6.0-7.8) 5.2 (4.9-6.2) 6.1 (4.1-7.7)
Occupational therapist 4 4 100.0 2.0 (1.4-3.7) 5.5 (3.2-5.7) 4.7 (0.0-6.4) 4.7 (0.0-6.8)
Auxiliary in pharmacy 9 11 81.8 1.5 (0.0-3.1) 5.9 (4.0-7.1) 2.2 (0.0-6.5) 6.7 (0.0-9.2)
Administrative officer 5 11 45.4 0.6 (0.0-1.6) 5.8 (3.9-7.0) 5.8 (4.3 -7.0) 5.2 (0.0-6.9)
Nursing staff
Nurse 26 58 44.8 3.3 (0.7-5.2) 5.5 (2.2-7.7) o0.0001* 4.9 (0.0-7.2) 6.0 (0.0-8.9) o0.0001*
Auxiliary nurse 93 219 42.5 2.0 (0.0-5.9) 5.4 (0.9-8.1) 2.0 (0.0-8.0) 4.0 (0.0-9.2)
TOTAL 173 421 2.3 (0.0-6.6) 5.2 (0.9-9.3) o0.0001* 3.9 (0.0-8.0) 5.2 (0.0-9.2) o0.0001*
Note:
Mi=median
Min=minimum
Max=maximum
NA=not applicable.
* Significant value.
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linear regression model, the MEI significantly contributed to
the increase in the number of ADE reports (p=0.0005).
Regarding the period of effectiveness of the MEI, a
decrease of 2.5% (3.9% compared with 1.4%) was noted in
the prevalence of ADEs reported four months after the MEI
was implemented (Figure 1). However, the ADE reporting
rate did not return to its pre-intervention level. Subsequent
increases in the prevalence of ADE reporting (3.4% and 3.5%)
(Figure 1) occurred due to the implementation of policies
regarding risk management and patient safety at the
institution.
Serious ADRs were reported by pharmacists (N=6) and
physiotherapists (N=1). The nursing staff submitted the most
ADE reports (150), followed by pharmacists (N=29), physi-
cians (N=6) and auxiliary nursing staff members (N=3). The
professional classification of twenty-six professionals who
reported ADEs could not be determined. Medication errors
(N=136) and quality deviations (N=10) were often reported
by the nursing staff, whereas ADRs (N=14) were reported by
pharmacists, and therapeutic failures (N=5) were reported by
physicians.
A broad spectrum of medication errors were reported after
the MEI, whereas no ADEs related to medication errors were
reported prior to the MEI (Figure 2). Administration errors
were the most frequently identified errors (Figure 2), and
these related mainly to the delayed intake of a drug (N=23).
Two of the 26 ADR reports were of poor quality, as they
lacked information regarding the suspicious drug associated
with the event and the time of the onset of the event. The
remaining 24 ADR reports were well documented, which
enabled the detection of 29 clinical manifestations likely
induced by 19 different drugs. With the exception of four
events, whose likelihood of being drug-related was remote
(alternative causes may explain these events), all the events
were expected ADRs. Seven of these were considered serious
for the following reasons: increased hospital stay (N=4),
temporary disability (N=2) and induced hospitalization
(N=1).
’ DISCUSSION
This study indicates that using MEIs with multidisciplin-
ary teams has a positive effect on the awareness of hospital
staff with respect to the importance of ADE reporting. An
increase exceeding 100% in the absolute number of reports of
drug-induced events was observed in the current research.
The strategies applied in the intervention improved the
participants’ knowledge of pharmacovigilance and increased
their skills in correctly filling out report forms, primarily in
relation to medication errors. Therefore, including hospital
professionals in pharmacovigilance services may contribute
to patient safety (25) by stimulating the detection of harmful
drug-induced events and the development of strategies
designed to prevent such events.
In recent years, legislation regarding pharmacovigilance
has been modified and updated to widen the scope of
post-marketing surveillance and improve individual patient
care (26). The primary goal of efforts to increase commu-
nication about drug-related problems is to facilitate medica-
tion error reporting and subsequently learn from those errors
in order to contribute to the safe and effective use of
medicines for the benefit of patients and public health (27).
To ensure a safe environment for drug therapy during all
stages of a medicinal product’s life cycle, it is necessary to
increase the involvement of healthcare professionals in
pharmacovigilance (5).
A systematic review suggests that interprofessional colla-
borations promote benefits to healthcare assistance and
improve patient outcomes (28). Engaging a multidisciplinary
team in an educational intervention for pharmacovigilance
revealed a remarkable increase in the prevalence of medica-
tion error reporting, mainly by the nursing staff. More-
over, the study observed drug-induced events associated
with harm to the patient that went unreported prior to the
MEI.
Therefore, our findings highlight the importance of adopt-
ing a multidisciplinary perspective to address the importance
of pharmacovigilance in contributing to patient safety and
enhancing the quality of reports related to medication errors
(29). Recognizing events that could potentially be prevented is
fundamental to identifying weaknesses in risk management
procedures (30) and designing policies to improve safety
protocols.
In this study, physiotherapists reported serious ADRs,
corroborating the interdisciplinary nature of pharmacovigi-
lance activities and their relation to patient safety (31), since
these professionals are also able to recognize idiosyncratic
events (32,33). Therefore, physiotherapists play an important
role in contributing to drug safety analysis and to the
prevention, early detection and communication of ADEs
(33). Furthermore, clinical pharmacists follow up on the
safety of pharmacotherapy and can contribute to improving
the early detection of drug-induced harm. Physicians are
focused on patient diagnoses; therefore, monitoring the
effectiveness of a prescribed treatment is fundamental to
assessing improvements in clinical outcomes and determin-
ing the target for the best pharmacotherapy.
Although nutritionists, psychologists, occupational thera-
pists and administrative officers did not submit any ADE
reports following the MEI, these professionals described
suspicious events in patient records. While these drug-
related problems were not appropriately communicated
through ADE reports, there was an improvement in risk
communication in patient charts.
Even though a substantial fraction of the hospital’s
professionals did not complete the four sessions (i.e., a low
rate of return for the questionnaire), we can conclude that the
MEI related to pharmacovigilance instilled a culture of drug
safety at our institution. Our hypothesis was consubstan-
tiated by the higher-quality information included in patient
records. Irrespective of whether professionals formally
reported ADEs to the risk management team at the hospital,
they were able to enhance the ADE reporting rate by 10%
(data not shown).
Regarding the period of the MEI’s effectiveness, the number
of ADE reports decreased after the first four months, and the
same behaviour was noted in the literature (2,34). The period
during which the rate of ADE reporting drops after educa-
tional interventions depends on the techniques applied in the
intervention, the level of healthcare and the professionals
enrolled in the intervention (34-35). Therefore, the data suggest
the need for periodic educational interventions to maintain
motivation among professionals regarding ADE reporting.
It is important to highlight that the subsequent increases
observed in ADE reporting coincided with the implementa-
tion of patient safety policies and the deployment of a
hospital risk management team. Therefore, both strategies
(risk-management policies and educational interventions)
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are inextricably linked in efforts to follow up on drug safety
and treatment effectiveness in hospitals.
The tradition of pharmacovigilance is a recent arrival in
Latin America, and there are few publications related to
pharmacovigilance (2). Additional studies are necessary to
assess the impact of ADE in low- and middle-income
countries (5). Consequently, our educational initiative is
relevant to efforts endeavouring to motivate volunteers to
increase post-marketing surveillance, decrease underreport-
ing, address the new trends derived from legislation and
contribute to learning about ADE.
Limitations of the study
The findings of this study should be considered in the
context of the study’s two primary design limitations. First,
randomized controlled trials are considered the gold
standard for evaluating the effectiveness of an intervention.
However, before-and-after intervention designs are ideal if
conducting a randomized controlled trial is either logistically
or ethically not possible. Second, during the follow-up period
for the MEI’s effectiveness, a policy regarding risk manage-
ment and patient safety was deployed in our hospital.
However, the implementation of this policy did not involve
providing hospital staff members with training related to
pharmacovigilance activities.
The MEI implemented for hospital staff in this study
improved the relevance of ADE reports and increased the
prevalence of such reports. Furthermore, the MEI was
effective at enhancing awareness (knowledge) of pharma-
covigilance, even among individuals who did not complete
all the intervention protocols or return the questionnaire.
This MEI can motivate the members of a multidisciplinary
Figure 1 - Adverse drug event prevalence detected via voluntary reporting by professionals before (t0) and after the educational
intervention (t2) in a public and general hospital. Ame´rico Brasiliense-SP (Brazil).
Figure 2 - Absolute number of medication error reports made by professionals after the educational intervention (t2) (no reports of this
type were made prior to the research) according to aetiology and seriousness (N=166). Ame´rico Brasiliense-SP (Brazil).
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team to change their behaviours/attitudes and can con-
tribute to improving the team members’ skills in detecting
new and relevant ADEs. Therefore, the inclusion of hospital
staff in drug safety analysis is an important strategy to
decrease ADE underreporting and improve the communica-
tion risks associated with drug use.
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